Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity

Detalhes bibliográficos
Autor(a) principal: Gomes,Cristiano M.
Data de Publicação: 2010
Outros Autores: Castro Filho,Jose E. de, Rejowski,Ronald F., Trigo-Rocha,Flavio E., Bruschini,Homero, Barros Filho,Tarcisio E. P. de, Srougi,Miguel
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000100011
Resumo: PURPOSE: To report our experience with the use of the botulinum toxin-A (BoNT/A) formulations Botox® and Prosigne® in the treatment of neurogenic detrusor overactivity (NDO). MATERIALS AND METHODS: At a single institution, 45 consecutive patients with refractory urinary incontinence due to NDO received a single intradetrusor (excluding the trigone) treatment with botulinum toxin type A 200 or 300 units. Botox was used for the first 22 patients, and Prosigne for the subsequent 23 patients. Evaluations at baseline and week 12 included assessment of continence and urodynamics. Safety evaluations included monitoring of vital signs, hematuria during the procedure, hospital stay, and spontaneous adverse event reports. RESULTS: A total of 42 patients were evaluated (74% male; mean age, 34.8 years). Significant improvements from baseline in maximum cystometric capacity (MCC), maximum detrusor pressure during bladder contraction, and compliance were observed in both groups (P < 0.05). Improvement in MCC was significantly greater with Botox versus Prosigne (+103.3% vs. +42.2%; P = 0.019). Continence was achieved by week 12 in 16 Botox recipients (76.2%) and 10 Prosigne recipients (47.6%; P = 0.057). No severe adverse events were observed. Mild adverse events included 2 cases of transient hematuria on the first postoperative day (no specific treatment required), and 3 cases of afebrile urinary tract infection. CONCLUSIONS: Botox and Prosigne produce distinct effects in patients with NDO, with a greater increase in MCC with Botox. Further evaluation will be required to assess differences between these formulations.
id SBU-1_f39b08b7fcf10069ea0f6bb07b7261aa
oai_identifier_str oai:scielo:S1677-55382010000100011
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivitybotulinum toxinsurinary bladder/overactiveneurogenic bladderurinary incontinenceurodynamicsPURPOSE: To report our experience with the use of the botulinum toxin-A (BoNT/A) formulations Botox® and Prosigne® in the treatment of neurogenic detrusor overactivity (NDO). MATERIALS AND METHODS: At a single institution, 45 consecutive patients with refractory urinary incontinence due to NDO received a single intradetrusor (excluding the trigone) treatment with botulinum toxin type A 200 or 300 units. Botox was used for the first 22 patients, and Prosigne for the subsequent 23 patients. Evaluations at baseline and week 12 included assessment of continence and urodynamics. Safety evaluations included monitoring of vital signs, hematuria during the procedure, hospital stay, and spontaneous adverse event reports. RESULTS: A total of 42 patients were evaluated (74% male; mean age, 34.8 years). Significant improvements from baseline in maximum cystometric capacity (MCC), maximum detrusor pressure during bladder contraction, and compliance were observed in both groups (P < 0.05). Improvement in MCC was significantly greater with Botox versus Prosigne (+103.3% vs. +42.2%; P = 0.019). Continence was achieved by week 12 in 16 Botox recipients (76.2%) and 10 Prosigne recipients (47.6%; P = 0.057). No severe adverse events were observed. Mild adverse events included 2 cases of transient hematuria on the first postoperative day (no specific treatment required), and 3 cases of afebrile urinary tract infection. CONCLUSIONS: Botox and Prosigne produce distinct effects in patients with NDO, with a greater increase in MCC with Botox. Further evaluation will be required to assess differences between these formulations.Sociedade Brasileira de Urologia2010-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000100011International braz j urol v.36 n.1 2010reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/S1677-55382010000100011info:eu-repo/semantics/openAccessGomes,Cristiano M.Castro Filho,Jose E. deRejowski,Ronald F.Trigo-Rocha,Flavio E.Bruschini,HomeroBarros Filho,Tarcisio E. P. deSrougi,Migueleng2010-04-20T00:00:00Zoai:scielo:S1677-55382010000100011Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2010-04-20T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
title Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
spellingShingle Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
Gomes,Cristiano M.
botulinum toxins
urinary bladder/overactive
neurogenic bladder
urinary incontinence
urodynamics
title_short Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
title_full Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
title_fullStr Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
title_full_unstemmed Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
title_sort Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
author Gomes,Cristiano M.
author_facet Gomes,Cristiano M.
Castro Filho,Jose E. de
Rejowski,Ronald F.
Trigo-Rocha,Flavio E.
Bruschini,Homero
Barros Filho,Tarcisio E. P. de
Srougi,Miguel
author_role author
author2 Castro Filho,Jose E. de
Rejowski,Ronald F.
Trigo-Rocha,Flavio E.
Bruschini,Homero
Barros Filho,Tarcisio E. P. de
Srougi,Miguel
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Gomes,Cristiano M.
Castro Filho,Jose E. de
Rejowski,Ronald F.
Trigo-Rocha,Flavio E.
Bruschini,Homero
Barros Filho,Tarcisio E. P. de
Srougi,Miguel
dc.subject.por.fl_str_mv botulinum toxins
urinary bladder/overactive
neurogenic bladder
urinary incontinence
urodynamics
topic botulinum toxins
urinary bladder/overactive
neurogenic bladder
urinary incontinence
urodynamics
description PURPOSE: To report our experience with the use of the botulinum toxin-A (BoNT/A) formulations Botox® and Prosigne® in the treatment of neurogenic detrusor overactivity (NDO). MATERIALS AND METHODS: At a single institution, 45 consecutive patients with refractory urinary incontinence due to NDO received a single intradetrusor (excluding the trigone) treatment with botulinum toxin type A 200 or 300 units. Botox was used for the first 22 patients, and Prosigne for the subsequent 23 patients. Evaluations at baseline and week 12 included assessment of continence and urodynamics. Safety evaluations included monitoring of vital signs, hematuria during the procedure, hospital stay, and spontaneous adverse event reports. RESULTS: A total of 42 patients were evaluated (74% male; mean age, 34.8 years). Significant improvements from baseline in maximum cystometric capacity (MCC), maximum detrusor pressure during bladder contraction, and compliance were observed in both groups (P < 0.05). Improvement in MCC was significantly greater with Botox versus Prosigne (+103.3% vs. +42.2%; P = 0.019). Continence was achieved by week 12 in 16 Botox recipients (76.2%) and 10 Prosigne recipients (47.6%; P = 0.057). No severe adverse events were observed. Mild adverse events included 2 cases of transient hematuria on the first postoperative day (no specific treatment required), and 3 cases of afebrile urinary tract infection. CONCLUSIONS: Botox and Prosigne produce distinct effects in patients with NDO, with a greater increase in MCC with Botox. Further evaluation will be required to assess differences between these formulations.
publishDate 2010
dc.date.none.fl_str_mv 2010-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000100011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000100011
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1677-55382010000100011
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.36 n.1 2010
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318071597236224